Vis børsmeldingen
ArcticZymes Technologies (AZT) has signed an exclusive licensing agreement with
UiT The Arctic University of Norway (UiT) for a novel DNA assembly technology.
The technology was developed by researchers at UiT and is based on unique heat
-labile enzymes identified by marine bioprospecting in the Arctic. The patent
-pending technology comprises novel enzymes with tailor-made characteristics for
controlled and efficient assembly of multiple DNA fragments.
DNA assembly is a work-horse technology serving a growing demand for gene- and
vector- constructs, enabling innovation in areas such as synthetic biology and
in the development of therapeutics. Synthetic biology is a growing
multidisciplinary field seeking to take advantage of synthetic genes and
genomes, generating new and improved biological systems to solve challenges in
medicine, manufacturing, and applied markets. The global synthetic biology
market was estimated at $9.6 billion in 2021 and projected to grow at a compound
annual growth rate (CAGR) of 26%.
By acquiring this technology, the Company will expand its offering towards new
and existing customers in both the molecular tools and biomanufacturing
businesses.
ArcticZymes Technologies ASA, CEO, Jethro Holter said:
"DNA assembly technologies are being utilised by biomanufacturers and service
providers, or offered as molecular tools for integration into application
workflows. The technology licensed by AZT will circumvent limitations in current
technologies.
We are delighted to enter into a further agreement with UiT. It builds on our
long-term partnership which has been successful in commercialising multiple
discoveries."
UiT The Arctic University of Norway, Head of Department, Department of
chemistry, Annette Bayer said:
“This technology is a great achievement for UiT, our researchers, collaborators,
and the Norwegian Research Council, and can enable technology advances in
important areas in the future. We are happy to have entered an agreement with an
experienced partner like ArcticZymes to make the technology available”.
For more information, please contact:
CEO, Jethro Holter Tel: +47 46 85 91 46
CFO, Børge Sørvoll Tel: +47 95 29 01 87
ir@arcticzymes.com
About ArcticZymes Technologies ASA
ArcticZymes Technologies is a Norwegian life sciences company focused on the
development, manufacturing and commercialization of novel recombinant enzymes
for use in molecular research, In Vitro Diagnostics (IVD) and biomanufacturing.
Listed on the Oslo Stock Exchange since 2005 originally under the [Biotec]
ticker, as Biotec Pharmacon. The company rebranded as ArcticZymes Technologies
in 2020 under the [AZT] ticker. Its headquarters are based in Tromsø, Norway, at
the SIVA Innovation Centre.
ArcticZymes Technologies’ IP and capabilities are protected via a large
portfolio of patents.
For more information, please visit the website: www.arcticzymes.com.
UiT The Arctic University of Norway
The Arctic University of Norway is the northernmost university of the world. Its
location on the edge of the Arctic implies a mission. The Arctic is of
increasing global importance. Climate change, the exploitation of Arctic
resources and environmental threats are topics of great public concern, and
which the University of Tromsø takes special interest in.
UiT’s key research focuses on the polar environment, climate research,
indigenous people, peace and conflict transformation, telemedicine, medical
biology, space physics, fishery science, marine bioprospecting, linguistics and
computational chemistry.
For more information, please visit the website: UiT The Arctic University of Norway | UiT
Kilde
